Mann H J, Fuhs D W, Hemstrom C A
Drug Intell Clin Pharm. 1986 Jun;20(6):421-38. doi: 10.1177/106002808602000602.
Acute renal failure (ARF) is common among critically ill patients and renal dysfunction is often associated with the multisystem organ failure syndrome. The mortality of ARF remains high but animal data indicate that prevention and early treatment may decrease the morbidity and mortality. This review defines ARF based on urine volume, laboratory parameters, and clinical presentation. The pathophysiology of prerenal, postrenal, and intrinsic ART are differentiated and diagnostic criteria provided. Preventive therapy, supportive care, and proposed treatments are outlined. Studies examining the prevention and treatment of ARF in animal models and trials in humans are evaluated. Mannitol 0.5-1 g/kg, furosemide 0.5-1 mg/kg initially, and dopamine 1-5 micrograms/kg/min are effective in preventing or decreasing the severity of ARF in animal models. In humans these drugs are effective at maintaining urine output in various clinical situations and converting oliguria to nonoliguria in some patients; however, increased survival has not been adequately proven as of yet. Dialysis and experimental therapy are briefly discussed.
急性肾衰竭(ARF)在危重症患者中很常见,且肾功能障碍常与多系统器官衰竭综合征相关。ARF的死亡率仍然很高,但动物实验数据表明,预防和早期治疗可能会降低发病率和死亡率。本综述根据尿量、实验室参数和临床表现来定义ARF。区分了肾前性、肾后性和肾性急性肾衰竭的病理生理学,并给出了诊断标准。概述了预防性治疗、支持性护理及建议的治疗方法。对在动物模型中研究ARF预防和治疗的研究以及人体试验进行了评估。在动物模型中,0.5 - 1 g/kg的甘露醇、初始剂量为0.5 - 1 mg/kg的呋塞米以及1 - 5微克/千克/分钟的多巴胺可有效预防或减轻ARF的严重程度。在人类中,这些药物在各种临床情况下对维持尿量有效,并且能使一些患者的少尿转变为非少尿;然而,截至目前,其对提高生存率的效果尚未得到充分证实。本文还简要讨论了透析和实验性治疗。